Education
About Us
Working with TipRanks
Follow Us
QuiaPEG Pharmaceuticals Holding AB (SE:QUIA)
:QUIA
Top Page
QuiaPEG Pharmaceuticals Holding AB
(Frankfurt:QUIA)
32Underperform
QuiaPEG Pharmaceuticals Holding AB (QUIA) vs. S&P 500 (SPY)
Market Cap
kr22.73M
Dividend YieldN/A
Average Volume (3M)20.91M
Price to Earnings (P/E)―
Beta (1Y)-3.32
Revenue GrowthN/A
EPS Growth97.86%
CountrySE
Employees5
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,124,285,000
10 Day Avg. Volume50,967,738
30 Day Avg. Volume20,912,490
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
QuiaPEG Pharmaceuticals Holding AB Business Overview & Revenue Model
Company DescriptionQuiaPEG Pharmaceuticals Holding AB (QUIA) is a Swedish biotechnology company focused on developing and commercializing advanced drug delivery systems. The company specializes in the PEGylation of pharmaceuticals, which involves attaching polyethylene glycol (PEG) polymers to drugs to enhance their therapeutic properties. This technology is aimed at improving drug stability, solubility, and half-life, thereby optimizing the efficacy of various treatments. QuiaPEG's core products are centered around its proprietary Uni-Qleaver technology platform, which is designed to facilitate controlled release and targeted delivery of pharmaceutical compounds.
How the Company Makes MoneyQuiaPEG Pharmaceuticals Holding AB generates revenue primarily through the licensing of its proprietary drug delivery technologies to pharmaceutical companies. The company enters into collaborative agreements with other biotech and pharmaceutical firms, allowing them to utilize QuiaPEG's PEGylation technology in the development of their own drug compounds. Revenue streams include upfront payments, milestone payments, and royalties on sales of successfully commercialized products using its technology. Additionally, QuiaPEG may engage in co-development partnerships, sharing both the risks and rewards of bringing new drugs to market. Strategic alliances and partnerships play a significant role in the company's earnings, leveraging the expertise and distribution networks of larger pharmaceutical entities to expand the reach and impact of its technology.
QuiaPEG Pharmaceuticals Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 4.99M | 0.00 | 4.37M | 5.57M | 216.00K | 1.86M | Gross Profit |
| 3.69M | 460.00K | 2.17M | 8.91M | 527.00K | -2.99M | EBIT |
| -13.57M | -28.66M | -15.51M | -15.79M | -17.57M | -24.93M | EBITDA |
| -11.45M | -9.71M | -13.43M | -13.98M | -16.01M | -23.67M | Net Income Common Stockholders |
| -13.86M | -28.93M | -16.52M | -24.38M | -22.43M | -30.49M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.52M | 2.00K | 101.00K | 2.57M | 5.34M | 8.59M | Total Assets |
| 15.12M | 22.75M | 41.96M | 23.44M | 23.76M | 20.54M | Total Debt |
| 2.34M | 0.00 | 20.61M | 15.52M | 17.80M | 15.75M | Net Debt |
| -5.18M | -2.00K | 20.51M | 12.96M | 12.46M | 7.16M | Total Liabilities |
| 10.59M | 6.39M | 26.71M | 21.03M | 23.74M | 20.47M | Stockholders Equity |
| 4.53M | 16.35M | 15.25M | 2.41M | 22.00K | 71.00K |
| Cash Flow | Free Cash Flow | ||||
| -6.86M | -10.63M | -34.64M | -23.75M | -28.70M | -30.81M | Operating Cash Flow |
| -6.86M | -10.17M | -10.27M | -18.18M | -20.11M | -28.31M | Investing Cash Flow |
| -22.63M | -460.00K | -24.37M | -5.57M | -8.59M | -2.50M | Financing Cash Flow |
| 28.68M | 10.53M | 32.17M | 20.98M | 25.46M | 34.86M |
QuiaPEG Pharmaceuticals Holding AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
49 Neutral | kr46.73M | ― | -47.01% | ― | -94.12% | -25.83% | |
40 Underperform | kr51.57M | ― | -55.51% | ― | -57.26% | 72.71% | |
32 Underperform | kr22.73M | ― | -180.43% | ― | ― | 97.86% | |
31 Underperform | kr2.65M | ― | -186.04% | ― | ― | 57.91% |
* Healthcare Sector Average
Performance Comparison
SE:QUIA
QuiaPEG Pharmaceuticals Holding AB
0.01
-0.05
-81.36%
SE:COMBI
CombiGene AB
2.41
-1.35
-35.90%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
19.40
-74.26
-79.29%
SE:SCOL
Scandion Oncology A/S
0.01
-0.80
-98.64%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.